Http://www.infinata5.com/biopharm/accesspoint.aspx?action=displ
Headline Company: Marina retains Numoda for Phase Ib/IIa trial of lead compound; open to Mdrna, Inc (FKA: Nastech Pharmaceuticals) contact from other CROs for pivotal Phase IIb - CEO Pfizer, Inc. Intelligence Details Numoda Corporation Marina Biotech (NASDAQ:MRNA) will work with the CRO Numoda Corp for the Phase Ib/IIa trial of its lead compound, CEQ508, in familial adenomatous